Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | MPI | P34949 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL805880 | 0.92 | MPI (0.60) | CYP1A2CYP2C9MPIKMT2APLA2G4B | |
| SCHEMBL804302 | 0.89 | MPI (0.65) | CYP1A2CYP2C9MPIHRH3 | |
| SCHEMBL804282 | 0.85 | CYP1A2 (0.77) | CYP1A2CYP2C9MPINR4A2 | |
| SCHEMBL787280 | 0.85 | MPI (0.60) | CYP1A2CYP2C9MPIPLA2G4B | |
| SCHEMBL787090 | 0.80 | CYP1A2 (0.79) | CYP1A2CYP2C9MPINR4A2 | |
| SCHEMBL804299 | 0.80 | MPI (0.67) | CYP1A2CYP2C9MPIKMT2A | |
| SCHEMBL787264 | 0.79 | CYP1A2 (0.70) | CYP1A2CYP2C9MPI | |
| SCHEMBL787380 | 0.78 | CYP1A2 (0.67) | CYP1A2CYP2C9MPI | |
| SCHEMBL804655 | 0.76 | CYP2C9 (0.76) | CYP1A2CYP2C9MPINR4A2 | |
| SCHEMBL2371334 | 0.75 | MPI (0.56) | CYP1A2CYP2C9MPIHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748632-B2 | Positive allosteric modulators of group II mGluRs | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120071503-A1 | POSITIVE ALLOSTERIC MODULATORS OF GROUP II MGLURS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071503-A1 | POSITIVE ALLOSTERIC MODULATORS OF GROUP II MGLURS | GRM2, GRM1, GRIN2C | CYP1A2 3286/4885CYP2C9 3909/4885MPI 4265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.